At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 22 enrolled
Drug / intervention
MK0893 +2 moredrug
Likely dose
MK0893 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled, Single-Dose Crossover Study to Assess the Safety and Tolerability of MK0893 Coadministered With Propranolol Hydrochloride in Patients With Type 2 Diabetes
In Brief
A Phase 1 clinical trial evaluating MK0893, MK0893-matched Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 22 participants.
Detailed Summary
This study will assess the effect of combined treatment with MK0893 plus propranolol versus placebo plus propranolol on hypoglycemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
First PostedMay 2009
Primary CompletionOct 2009
Study CompletionNov 2009
TodayJul 2026
First PostedMay 15, 2009
Enrollment StartMay 1, 2009
Primary CompletionOct 1, 2009
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.1 years ago
Interventions
MK0893drug
Single dose of MK0893 1000 mg (ten 100 mg tablets)
MK0893-matched Placebodrug
Single dose of placebo to MK0893 (ten tablets)
Propranolol Hydrochloride (HCL)drug
Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.